Overview of Chronic Induced Urticaria
Chronic induced urticaria (CIndU) is a subtype of chronic urticaria that is triggered by specific physical or environmental factors such as pressure, temperature fluctuations, sunlight, exercise, etc. Unlike chronic spontaneous urticaria, which has no apparent cause, CIndU is triggered by an identifiable stimulus, making it unpredictable and difficult to manage.
The condition is caused by an overactive immune response, which causes mast cells to release histamines and inflammatory mediators when they encounter a trigger, resulting in symptoms like itching, redness, and swelling. Treatment typically includes antihistamines, leukotriene receptor antagonists, and in severe cases, immunomodulatory therapies to help control symptoms.
For a comprehensive report on Chronic Induced Urticaria pipeline insights, please see below: https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
Key Takeaways from the Chronic Induced Urticaria Pipeline Report
DelveInsight's chronic induced urticaria pipeline report paints a robust picture with more than four active companies developing treatments for chronic induced urticaria, with more than four therapies in development.
Key companies in the CIndU space, including Celldex Therapeutics and Jasper Therapeutics, are researching new drug candidates to enhance current treatment options.
Promising therapies in the pipeline include varzolvolimab, which is in various stages of clinical development.
Recent advances in the chronic induced urticaria pipeline
- December 2024: Jasper Therapeutics reported encouraging early results from its Phase 1b/2a SPOTLIGHT study of burquilimab, a mast cell-targeting monoclonal antibody. CIndU patients demonstrated rapid and significant responses, with 93% achieving a partial or complete response within six weeks. The treatment was well tolerated and there were no serious adverse events, highlighting the potential of burquilimab as a novel treatment for CIndU.
- August 2024 Nemolizumab, an IL-31 receptor antagonist, has received FDA approval for the treatment of atopic dermatitis, with further approval expected in the EU by February 2025. The drug may provide insight into CIndU treatment, given its mechanism of action to prevent proinflammatory responses.
- October 2024: Celldex Therapeutics announced positive Phase 2 results for varzolvolimab, a monoclonal antibody targeting the KIT receptor tyrosine kinase. The study met its primary and secondary endpoints with high statistical significance, establishing varzolvolimab as the first treatment to demonstrate clinical benefit in a large randomized trial. Celldex plans to advance to Phase 3 trials in 2025.
Chronic Induced Urticaria Pipeline Analysis
The report provides detailed insights into:
- More information on companies developing treatments for chronic induced urticaria.
- Analysis of potential treatments categorized by development stage (early, mid, late stage).
- Assessment of active and inactive (dormant or discontinued) projects by key companies.
- Gain insights into emerging drugs based on their stage of development, route of administration, target receptor, and whether they are monotherapy or combination therapy.
- Collaborations (business-to-business and business-academia), licensing agreements, and fundraising activities are crucial to the future development of the CIndU market.
To download a free sample report on Chronic Induced Urticaria Pipeline Insights, please visit: https://www.delveinsight.com/sample-request/chronic-inducible-urticaria-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
Chronic induced urticaria: New drugs
- Valzolvolimab: Celldex Therapeutics
Valzorvolimab is a humanized monoclonal antibody developed by Celldex Therapeutics. It specifically targets the KIT receptor tyrosine kinase, which is important for mast cell function and survival. By inhibiting this receptor, valzorvolimab aims to control mast cell-driven inflammatory responses in conditions like CIndU. It is currently in Phase II trials for the treatment of CINDU.
Major Players in Chronic Induced Urticaria
Several prominent companies are leading the development of treatments for chronic induced urticaria: Celldex Therapeutics has one of the most advanced drug candidates currently in Phase II clinical trials.
DelveInsight's report features no fewer than four products at various stages of development.
- Post-production(Phase III)
- Mid-term products(Phase II)
- Early Stage Products(Phase I)
- Preclinical and discovery stage candidates
- Discontinued and inactive candidates
Chronic Induced Urticaria Pipeline Treatment Evaluation
This report provides a therapeutic assessment of CIndU pipeline drugs through:
- Product Type
- Developmental stages
- Route of administration(IV, subcutaneous, oral, intramuscular)
- Molecular Type(monoclonal antibodies, small molecules, peptides)
To gain further insight into the novel treatment for chronic induced urticaria, download the sample report here. Treatment evaluation of chronically induced urticaria
table of contents
- Introduction to the report
- Executive Summary
- Current treatment patterns for chronic induced urticaria
- Chronic Induced Urticaria – A DelveInsight Analysis Perspective
- Treatment evaluation
- Chronic induced urticaria Late stage product (Phase III)
- Chronic Induced Urticaria Mid-stage Products (Phase II)
- Early Stage Products (Phase I)
- Preclinical and discovery stage products
- Inactive Products
- Dormant products
- Discontinued products for chronic induced urticaria
- Chronic Induced Urticaria Product Profile
- Major players in Chronic Induced Urticaria
- Key products for chronic induced urticaria
- Inactive and Discontinued Products
- Unmet Need for Chronic Induced Urticaria
- Future prospects for chronic induced urticaria
- Chronic Induced Urticaria Analyst Review
- Appendix
- Reporting Methods
Request a sample PDF to get detailed insights into the Chronic Induced Urticaria Pipeline report offerings: https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
About DelveInsight
DelveInsight is a leading business consultancy and market research firm focused on life sciences, supporting pharmaceutical companies by providing comprehensive end-to-end solutions to improve their business performance.
Contact Information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
